ResMed Operating Margin from 2010 to 2026

RMD Stock  USD 245.73  13.29  5.13%   
ResMed's Operating Profit Margin is increasing over the years with slightly volatile fluctuation. Operating Profit Margin is expected to dwindle to 0.17.
Check ResMed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ResMed's main balance sheet or income statement drivers, such as Depreciation And Amortization of 284.7 M, Interest Expense of 11.9 M or Total Revenue of 6.2 B, as well as many indicators such as Price To Sales Ratio of 4.31, Dividend Yield of 0.0134 or PTB Ratio of 4.78. ResMed financial statements analysis is a perfect complement when working with ResMed Valuation or Volatility modules.
  
Build AI portfolio with ResMed Stock
Check out the analysis of ResMed Correlation against competitors.
Analyzing ResMed's Operating Margin over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Margin has evolved provides context for assessing ResMed's current valuation and future prospects.

Latest ResMed's Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of ResMed Inc over the last few years. It is ResMed's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ResMed's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.35 %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

ResMed Operating Margin Regression Statistics

Arithmetic Mean0.24
Geometric Mean0.23
Coefficient Of Variation22.40
Mean Deviation0.04
Median0.24
Standard Deviation0.05
Sample Variance0
Range0.2366
R-Value0.51
Mean Square Error0
R-Squared0.27
Significance0.03
Slope0.01
Total Sum of Squares0.05

ResMed Operating Margin History

2026 0.17
2025 0.29
2024 0.33
2020 0.28
2019 0.27
2016 0.21

About ResMed Financial Statements

ResMed stakeholders use historical fundamental indicators, such as ResMed's Operating Margin, to determine how well the company is positioned to perform in the future. Although ResMed investors may analyze each financial statement separately, they are all interrelated. For example, changes in ResMed's assets and liabilities are reflected in the revenues and expenses on ResMed's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ResMed Inc. Please read more on our technical analysis and fundamental analysis pages.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 8160 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:
Check out the analysis of ResMed Correlation against competitors.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Will Health Care Equipment & Supplies sector continue expanding? Could ResMed diversify its offerings? Factors like these will boost the valuation of ResMed. Anticipated expansion of ResMed directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ResMed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
0.145
Dividend Share
2.26
Earnings Share
10.1
Revenue Per Share
36.896
Quarterly Revenue Growth
0.11
ResMed Inc's market price often diverges from its book value, the accounting figure shown on ResMed's balance sheet. Smart investors calculate ResMed's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since ResMed's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between ResMed's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ResMed should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.